Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volitinib dose-escalation study in advanced solid tumors
ACTRN12613000133730Phase 2Recruiting
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of savolitinib in Nonhematologic neoplasms, sponsored by Hutchison MediPharma (HMP). Primary endpoints: Safety and tolerability of single and multiple doses of HMPL-504, Incidence and nature of dose-limiting toxicities and 1 more. Started Feb 2012; status: recruiting.
02
Drugs
savolitinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12613000133730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000133730.